CML Therapy Practice: Satellite Symposium

Chronic myelogenous leukemia (CML) is one of the major malignant disorder and accounts for 15%–20% of all cases of leukemia in adults. Despite enormous advancements in the understanding of the molecular etiology of CML and the development of novel therapeutic strategies, clinicians still face decision making challenges in the effective treatment of CML patients especially those with prior failed lines of therapy. The TKI therapies has successfully improved the overall survival in CML patients and has transformed CML disease from a fatal to a manageable disease. In recent years, there has been marked increase in the efficacy studies on TKIs usage in resistant CML therapy. These advancements make it difficult for Healthcare professionals (HCPs) to maintain current knowledge in a timely fashion. The overarching goal of this activity is to advance the HCP’s knowledge about latest efficacy updates about TKIs usage in CML management with prior failed lines of therapy, thereby reducing practice gaps by increasing confidence in new therapeutic decision making and ultimately improving the overall patience care.